Single photon emission computed tomography (SPECT) and positron emission tomography (PET) are increasingly used to understand differential diagnosis and pathophysiological progression of a variety of neurodegenerative and neuropsychiatric disorders. These techniques have also been instrumental in the process of drug discovery and development. Over the last decades, the development of high affinity and subtype-selective adenosine 2A (A2A) radiotracers has enable the non-invasive in vivo quantification of these receptors using SPECT and PET imaging. Data collected so far has confirmed the value of PET and SPECT techniques in assessing A2A changes in brain. These findings can foster the rapid widespread use of PET and SPECT A2A imaging, in particular now that suitable PET and SPECT probes with attractive in vivo properties are available for quantification of A2A in brain. In particular, the recent report of radiotracers labelled with fluorine-18 or iodine-123 that displayed improved binding potentials in vivo compared with radiotracers previously developed, provides the opportunity to further expand the global use of in vivo pre-clinical and clinical A2A imaging studies in neuroscience research. This book chapter provides a brief overview of the value of PET and SPECT in neuroscience, describes the key in vivo characteristics of PET and SPECT radiotracers developed to date for imaging A2A in brain and offers examples of previous pre-clinical and clinical studies that used PET and SPECT with A2A radiotracers to address a specific research question, with a particular focus on studies examining Parkinson's disease.
|Title of host publication||The Adenosinergic System|
|Subtitle of host publication||A Non-Dopaminergic Target in Parkinson's Disease|
|Publisher||Springer International Publishing AG|
|Number of pages||26|
|Publication status||Published - 9 Oct 2015|
- Parkinson's disease